Latest news with #ThermoFisherScientific
Yahoo
5 hours ago
- Business
- Yahoo
Institute for Supply Management® Honors Craig Reed with 2025 J. Shipman Gold Medal Award
Transformative supply chain executive honored with prestigious ISM® award ORLANDO, Fla., June 3, 2025 /PRNewswire/ -- Institute for Supply Management® (ISM®) named Craig Reed, CPSM, Vice President of Global Procurement and Chief Procurement Officer at Thermo Fisher Scientific, the 2025 J. Shipman Gold Medal Award winner in recognition of his distinguished service to the supply management profession. Reed was honored during the 2025 Awards Gala at ISM World 2025, ISM's annual international supply management conference, held June 1 - 3 in Orlando. The award, created in 1931, is ISM's most esteemed honor and is presented annually to an individual who contributes to the advancement of procurement and supply management while providing guidance to other professionals. "I am deeply honored and humbled to receive the J. Shipman Gold Medal Award. This recognition is a testament to the collective efforts and dedication of my colleagues, mentors, and the entire procurement community who have supported and inspired me throughout my career. I am grateful to the Institute for Supply Management® for this prestigious award and for their unwavering commitment to advancing the supply management profession. This accolade reflects not only my work but also the achievements of the talented teams I have had the privilege to lead and the innovative organizations I have been a part of. Thank you to everyone who has been a part of this journey. Together, we will continue to drive excellence and innovation in supply management," said Reed. Craig Reed has over 30 years of experience in procurement and supply chain management, spanning diverse industries including industrial, electrical, airline, automotive, commercial, consumer goods and life sciences. In his current role at Thermo Fisher Scientific, Craig leads a global procurement team of over 800 employees, managing spend critical to the company's operations, which generated more than $42M in revenue in 2024. His strategic initiatives have driven, cost productivity, margin expansion, supply assurance, risk management, quality improvement, supplier performance and organizational capability, development and effectiveness, making a significant impact on the company's global operations. Prior to joining Thermo Fisher Scientific, Craig served as the Chief Procurement Officer and Head of Corporate Real Estate and Facility Services at Corteva Agriscience, where he oversaw a global procurement team responsible for more than $9 billion in global spend. He has also held key procurement roles at DuPont, Eaton PLC, MeadWestvaco, Delta Air Lines, Deere & Company, BMW Manufacturing, and Honda of America Manufacturing. "It's nearly impossible to capture the full scope of Craig Reed's impact on the supply management profession. Craig's leadership at Thermo Fisher Scientific, one of the most complex procurement environments in the world, sets a benchmark for strategic excellence, operational rigor, and purpose-driven innovation. His unwavering commitment to sustainability, talent development, and inclusive leadership has reshaped what it means to be a supply chain executive today," said ISM CEO Thomas W. Derry. "As a leader and a tireless advocate for equity and representation, Craig has helped shape the future of our profession and has established a profound legacy." Reed's contributions to the profession extend beyond his corporate roles. He has been an active member of ISM, serving on the National Board of Directors and as Chair of the Board. He is also a founding member of the Black Executive Supply Summit and has been involved in numerous community and professional development activities, including mentoring students and supporting supplier development and diversity initiatives. Reed has been a consistent advocate for broadening representation in the profession across all dimensions: in his teams, in engaging diverse suppliers to promote a healthier supply ecosystem, and in developing the leadership structure of the profession itself. As a member of the board of ISM, and later its Chair, Craig held ISM accountable to serve as an organization that identified and developed professionals of all backgrounds. His focus on this need led to him serving as a member of the Board of Directors of the National Minority Supplier Development Council and being elected to the Board of Trustees of Florida A&M University, the number one ranked public Historically Black College/University (HBCU) in the United States. A passionate educator and leader, Reed has served as a guest lecturer and instructor at institutions including the Department of Defense, Michigan State University, North Carolina State University, Howard University, and Clark Atlanta University, where he also co-founded and chaired the Supply Chain Management Executive Advisory Board, helping establish a robust supply chain management curriculum. His influence spans globally—from teaching procurement in Dubai to speaking at premier conferences such as ISM and NMSDC. As a founding member of the Procurement Roundtable of Business Equity for Indy (BEI), Reed has championed supplier diversity and equitable access for MBEs. A published author and frequent panelist, his insights on topics like supplier performance, global sourcing, and boardroom metrics have shaped the future of procurement. Reed's legacy is one of innovation, mentorship, and unwavering commitment to advancing the field of supply management. Reed holds a Master of Business Administration in Supply Chain Management from the W.P. Carey School of Business at Arizona State University and a bachelor's degree in economics from Florida Agricultural and Mechanical University. About the J. Shipman Gold Medal Award Johnson Shipman was a pioneer member of the New York affiliate of the National Association of Purchasing Agents, now Institute for Supply Management®, well-known for giving liberally of his time and counsel. The J. Shipman Gold Medal Award was created in 1931, and is presented to those individuals whose modest, unselfish, sincere, and persistent efforts have aided the advancement of the procurement and supply chain management field. Those chosen for the award have also assisted and guided members of the profession in their endeavors. About Institute for Supply Management®Institute for Supply Management® (ISM®) is the first and leading not-for-profit professional supply management organization worldwide. Its community of more than 50,000 in more than 100 countries around the world manage about US$1 trillion in corporate and government supply chain procurement annually. Founded in 1915 by practitioners, ISM is committed to advancing the strategy and practice of integrated, end-to-end supply chain management through leading edge data-driven resources, community, and education to empower individuals, create organizational value and to drive competitive advantage. ISM's vision is to foster a prosperous, sustainable world. ISM empowers and leads the profession through the ISM® Report On Business®, its highly-regarded certification and training programs, corporate services, events and assessments. The ISM® Report On Business®, Manufacturing, Services, and Hospital are three of the most reliable economic indicators available, providing guidance to supply management professionals, economists, analysts, and government and business leaders. For more information, please visit: Contact: Jessica Boyd, 480.752.6276, ext. 3085jboyd@ View original content to download multimedia: SOURCE Institute for Supply Management
Yahoo
2 days ago
- Business
- Yahoo
Q1 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Thermo Fisher (NYSE:TMO) and its peers. The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.5% while next quarter's revenue guidance was 0.6% above. While some research tools & consumables stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.3% since the latest earnings results. With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE:TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide. Thermo Fisher reported revenues of $10.36 billion, flat year on year. This print exceeded analysts' expectations by 1.3%. Despite the top-line beat, it was still a mixed quarter for the company with a narrow beat of analysts' organic revenue estimates but a slight miss of analysts' operating income estimates. 'We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I'm incredibly proud of our team's execution,' said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. The stock is down 7.8% since reporting and currently trades at $400.50. Is now the time to buy Thermo Fisher? Access our full analysis of the earnings results here, it's free. Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized equipment, software, and services for biotechnology, life sciences, and diagnostics. Danaher reported revenues of $5.74 billion, flat year on year, outperforming analysts' expectations by 2.7%. The business had a very strong quarter with an impressive beat of analysts' organic revenue and EPS estimates. The market seems content with the results as the stock is up 3.1% since reporting. It currently trades at $190.50. Is now the time to buy Danaher? Access our full analysis of the earnings results here, it's free. With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries. Avantor reported revenues of $1.58 billion, down 5.9% year on year, falling short of analysts' expectations by 1.6%. It was a softer quarter as it posted a miss of analysts' organic revenue and EPS estimates. Avantor delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 16.5% since the results and currently trades at $12.91. Read our full analysis of Avantor's results here. With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use. Sotera Health Company reported revenues of $254.5 million, up 2.6% year on year. This number topped analysts' expectations by 3.1%. Overall, it was a strong quarter as it also logged a solid beat of analysts' organic revenue and EPS estimates. The stock is up 6.5% since reporting and currently trades at $12.24. Read our full, actionable report on Sotera Health Company here, it's free. With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Bruker reported revenues of $801.4 million, up 11% year on year. This print surpassed analysts' expectations by 4.3%. Aside from that, it was a satisfactory quarter as it also produced a solid beat of analysts' organic revenue estimates but a significant miss of analysts' full-year EPS guidance estimates. Bruker scored the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise among its peers. The stock is down 8.2% since reporting and currently trades at $36.21. Read our full, actionable report on Bruker here, it's free. As a result of the Fed's rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed's 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump's victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Business Wire
7 days ago
- Business
- Business Wire
Thermo Fisher Scientific Celebrates Precision Oncology Advancement at ASCO 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase some of the technologies that have helped power precision oncology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Through poster presentations, abstracts, and an end-to-end presence across oncology diagnostics, clinical trials, and drug development, Thermo Fisher will demonstrate how its integrated solutions – from biomarker discovery to commercialization – are improving access to targeted cancer therapies. By advancing NGS technologies that prioritize speed, accuracy, and accessibility, the company, through its clinical sequencing business, is helping to ensure that patients in all care settings benefit from the latest innovations. This year marks a significant milestone for Thermo Fisher: a decade of pharma partnership in NGS companion diagnostics development and commercialization, supporting new drug launches globally with decentralized in-country CDx solution. This commitment extends to its clinical research capabilities. Over the past five years, Thermo Fisher has supported more than 750 hematology and oncology clinical trials, involving over 175,000 patients at more than 35,000 sites in over 100 countries. Through its PPD™ clinical research business, the company takes a patient-centered approach to trial design and execution, ensuring that studies are not only scientifically rigorous but also more accessible and inclusive. 'Reflecting on the last decade of partnership with pharmaceutical companies and their therapeutic innovations, we're proud to continue our legacy as a trusted partner and celebrate the impact these collaborations have had on expanding access to precision cancer care,' said Kathy Davy, president of Clinical Next-Generation Sequencing at Thermo Fisher Scientific. 'Behind every test is a patient waiting for answers. That's what drives us – equipping clinicians with fast, reliable insights so they can make confident, timely treatment decisions that change lives.' Davy will deliver opening remarks at the Canadian Evening at ASCO 2025, hosted by Breast Cancer Canada. Held Friday, May 30, at the Marriott Marquis Chicago, this event brings together researchers, clinicians, advocates, and industry leaders to celebrate progress in cancer research. Research and Abstract Highlights at ASCO 2025 At ASCO 2025, researchers from Thermo Fisher and its customers will present new data on precision oncology, including: Assessment of Homologous Recombination Deficiency and BRCA Status (Abstract 3130, Poster presentation) - evaluates a decentralized NGS assay for identifying HRD and BRCA mutations in ovarian cancer. Combined Genomic Profiling of cfDNA and ctDNA – demonstrates how dual analysis of cfDNA and ctcDNA using a prostate cancer-specific panel can provide complementary molecular insights. Association between Targeted Therapy and Survival in Patients with AML (Abstract e23283 in collaboration with EVERSANA) - analyzes real-world data showing improved survival in high-risk MDS patients receiving targeted therapies based on genetic mutations. Attendees can connect with Thermo Fisher experts at booth #12049 to learn more about how the company supports oncology programs from research through commercialization. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
&w=3840&q=100)
Business Standard
24-05-2025
- Business
- Business Standard
HCG Q4 PAT drops 65% to ₹7.4 cr; acquires Orbitrap Astral from Thermo
Bengaluru-based HealthCare Global Enterprises (HCG) reported a 65 per cent decrease in consolidated profit after tax (PAT) to Rs 7.4 crore during the fourth quarter of the financial year ended March. HCG further announced the acquisition of the Orbitrap Astral Mass Spectrometer from Thermo Fisher Scientific. 'Looking ahead, we are making focused investments in next-generation capabilities, especially in early cancer detection and precision medicine. In line with our commitment to cutting-edge diagnostics and research, we are pleased to share that we are acquiring the Orbitrap Astral Mass Spectrometer from Thermo Fisher Scientific — one of the most advanced platforms globally for high-resolution mass spectrometry,' said BS Ajaikumar, executive chairman, HealthCare Global Enterprises. 'The acquisition will significantly enhance our molecular and proteomic profiling capabilities, enabling more precise disease characterisation and paving the way for next-generation biomarker discovery and targeted therapies,' said Ajaikumar. HCG reported operating income at Rs 585.1 crore in Q4FY25, up from Rs 494.6 crore in the same period last year. The company reported that revenues for HCG Onco Specialty Centres (excluding MGM) grew by a robust 16.7 per cent year-on-year in FY25. The quarter's earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at Rs 107 crore, a growth of 14 per cent while maintaining a margin a margin of 18.3 per cent. For the company's established centers, EBITDA grew 15 per cent at Rs 115.4 crore, and emerging centers witnessed a Rs 7 crore increase from Rs 4.9 crore, year-on-year. 'Continuing our strategic focus on inorganic growth, we acquired MG Hospital in Vizag in FY25, further consolidating our presence and establishing HCG as the leading cancer care provider in that region. This acquisition marks our third in just 18 months, highlighting our consistent and focused approach to expansion,' said Raj Gore, CEO HealthCare Global Enterprises. HCG further emphasised its long-term commitment to building a robust academic and research foundation. Through fellowship programs and clinical research initiatives, the organisation aims to nurture the next generation of oncology leaders.
Globe and Mail
22-05-2025
- Health
- Globe and Mail
HIV Diagnosis Market to Hit USD 5.31 Billion by 2030 with 10.3% CAGR
"The major market players involved in this market are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany)" Browse 332 market data Tables and 50 Figures spread through 273 Pages and in-depth TOC on "HIV Diagnostics Market by Product (Assay Kits & Reagents, Instrument, Software), Test Type (Rapid Test, ELISA, Western Blot, Viral Load, CD4 Test), End User (Diagnostic Laboratories, Homecare Settings, Hospital) - Global Forecast to 2030 The global HIV diagnosis market, valued at US$2.96 billion in 2024, is forecasted to grow at a robust CAGR of 10.3%, reaching US$3.25 billion in 2025 and an impressive US$5.31 billion by 2030. The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent. Efforts driven by government health initiatives and public awareness campaigns promoting HIV testing are significantly boosting market growth. Additionally, innovations in testing technologies, such as rapid tests and self-testing kits, along with improved accuracy and ease of use, are enhancing patient compliance and encouraging wider adoption. Despite these positive developments, challenges like the high cost of diagnostic tests and complex testing procedures may slow down growth. However, the market is expected to continue progressing steadily, fueled by a stronger emphasis on early detection, improved healthcare access, and the increasing availability of advanced, convenient testing solutions. Browse in-depth TOC on " HIV Diagnosis Market" 332 - Tables 50 - Figures 273 - Pages Based on product type, the HIV diagnostics market is divided into consumables, instruments and software& services. In 2024, the consumables segment accounted for the largest share of the HIV diagnostics market. The large share and the high growth rate of the consumables segment can be attributed to the frequent & repetitive purchase of consumables by laboratories and hospitals; the growing prevalence of HIV/AIDS; and favorable government initiatives to launch advanced consumables in the market. Based on Test Type, the HIV diagnostics market is segmented into screening tests, confirmatory tests and monitoring tests. The monitoring tests segment accounted for the largest share of the HIV diagnostics market in 2024. This segment is also expected to grow at the highest CAGR owing to the increasing awareness of HIV testing; the high volume of monitoring test samples; and the growing establishment of diagnostic laboratories for testing of HIV/AIDS. Additional factors include technological advancements in monitoring testing kits. Based on end users, the HIV diagnostics market is segmented into diagnostic laboratories, hospitals, blood banks, home cares settings and other end users. The diagnostic laboratories segment accounted for the largest share of the HIV diagnostics market in 2024. The large share of this segment owed to the increasing prevalence of HIV/AIDS; the rising establishment of diagnostic laboratories; growing sample testing; and advancements in PoC instruments. The HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominates the global market and is expected to continue during the forecast period. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North America. However, the Asia Pacific market is expected to grow at the highest CAGR of 12.5% during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this region. The major market players involved in this market are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others. ABBOTT (US) Abbott is the leading player in the HIV diagnostics market. The company has a strong presence in the US and seeks to enhance its geographical presence by strengthening its business operations in emerging markets. The company has a strong product portfolio, and its FDA- and CE-approved products have helped it gain a sizable market share. Abbott focuses on inorganic growth strategies, such as collaborations and acquisitions, to enhance its product portfolio and expand its geographical presence. The company's extensive research & development activities for product development and its ongoing clinical trials for newly developed products will further enhance its share in the HIV diagnostics market. SIEMENS HEALTHINEERS AG (GERMANY) Siemens Healthineers AG is among the leading players in the global HIV diagnostics market. The company provides a comprehensive portfolio of medical solutions, from medical imaging and in vitro diagnostics to interventional and clinical information technology systems. The company focuses on organic strategies, including product approvals, to enhance its presence in the global POC market. It also aims to create innovative products that address the unmet needs of patients and healthcare providers and take the first-mover advantage. The company also focuses on partnerships and collaborations to enhance its market presence. For instance, in December 2023, Siemens Healthineers AG and OU Health entered a 10-year value partnership to bring the latest diagnostic and therapeutic equipment to people across Oklahoma. THERMO FISHER SCIENTIFIC (US) Thermo Fisher Scientific is a key player in the global HIV diagnostics market, offering a comprehensive range of diagnostic solutions, including PCR-based assays, immunoassays, and molecular testing technologies. The company has a strong presence in developed and emerging markets, leveraging its advanced research capabilities and extensive distribution network. Thermo Fisher focuses on continuous innovation, regulatory approvals, and strategic acquisitions to expand its product portfolio. Additionally, the company collaborates with healthcare organizations and government agencies to enhance diagnostic accessibility and improve early detection of HIV. For more information, Inquire Now!
